Trustiva Tablet (Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg + Efavirenz 600mg)

What is Trustiva Tablet (Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg + Efavirenz 600mg)?

Trustiva Tablet is a complete antiretroviral regimen combining three active ingredients—emtricitabine, tenofovir disoproxil fumarate, and efavirenz—in a single tablet. It is prescribed for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents. By inhibiting key enzymes required for viral replication, Trustiva helps reduce viral load, maintain immune function, and delay progression to AIDS. It is not a cure for HIV or AIDS but is a critical component of long-term management strategies.

Key features

• Fixed-Dose Combination — Three antivirals in one tablet for simplified dosing.
• Once-Daily Use — Enhances adherence with convenient single-dose regimen.
• Viral Suppression — Effectively lowers HIV RNA levels in the blood.
• Immune Support — Helps increase CD4 cell counts to improve immune defense.
• Oral Administration — Taken by mouth, ideally on an empty stomach at bedtime.
• Prescription Required — Must be used under medical supervision with regular monitoring.
• WHO-Recommended Regimen — Efavirenz-based therapy included in global HIV treatment guidelines.

Who is Trustiva Tablet (Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg + Efavirenz 600mg) for?

This medication is intended for adults and children weighing at least 40 kg who are newly diagnosed with HIV-1 or switching from another regimen. It is not recommended for patients with severe liver disease or hypersensitivity to any component. Pregnant women or those planning pregnancy should consult a doctor due to efavirenz-related risks. Ideal candidates are those seeking a reliable, once-daily treatment with proven efficacy in resource-limited settings.

How does Trustiva Tablet (Emtricitabine 200mg + Tenofovir disoproxil fumarate 300mg + Efavirenz 600mg) compare?

Compared to newer integrase inhibitor-based regimens, Trustiva offers a lower-cost, widely available alternative with long-term safety data. While it remains effective, it may have more side effects—such as dizziness or rash—than modern alternatives like bictegravir or dolutegravir-based tablets. However, in regions where access and cost are barriers, Trustiva remains a cornerstone of HIV care due to its stability, simplicity, and global distribution.